Nancy J. Hutson - 18 Aug 2021 Form 4/A - Amendment Insider Report for PhaseBio Pharmaceuticals Inc

Role: Director
Signature: /s/ John P. Sharp, Attorney-in-fact
Issuer symbol: N/A
Transactions as of: 18 Aug 2021
Net transactions value: +$9,240
Form type: 4/A - Amendment
Filing time: 20 May 2022, 16:47:13 UTC
Date Of Original Report: 19 Aug 2021
Previous filing: 17 Aug 2021
Next filing: 19 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PHASQ	Common Stock	Purchase	$9,240	+3,000	+300%	$3.08^*	4,000	18 Aug 2021	Held in an individual retirement account for the benefit of the Reporting Person	F1
holding	PHASQ	Common Stock						33,760	18 Aug 2021	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.07 to $3.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.
F2	Amended to report direct share ownership.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.07 to $3.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

Amended to report direct share ownership.